Amendments in the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-4. (canceled)

Claim 5. (currently amended): A pharmaceutical composition comprising one or more of **[[the]]** compounds~~ as claimed in claim 1~~ **I**,



I

wherein

A is (C_1-C_8)alkyl, (C_0-C_8)alkylenearyl; a 3- to 12-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O, and S, and the 3- to 12-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C_1-C_6)alkyl, S-(C_1-C_6)alkyl, and NHCO(C_1-C_6)alkyl;

X is a bond, C(R8)(R9), C(OR10)(R11), O, N(R12), S, SO, SO_2, or CO;

R8, R9, R10, R11, R12 are, independently of one another, H or (C_1-C_6)alkyl;

D is N, or C(R41);

E is N, or C(R42);

G is N, or C(R43);

L is N, or C(R44);

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, Br, J, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)alkyl, (C_1-C_4)alkoxyalkyl, S-(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_3-C_8)cycloalkyl, O-(C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkenyl, O-(C_3-C_8)cycloalkenyl, (C_2-C_6)alkynyl, (C_0-C_8)alkylenearyl, -O-(C_0-C_8)alkylenearyl, S-aryl, N(R13)(R14), SO_2-CH_3, COOH, COO-(C_1-C_6)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), CO(R21), or a 5- to 7-membered heterocycle having 1-4 heteroatoms;

R13, R14 are, independently of one another, H, (C_1-C_6)alkyl, or R13 and R14, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R15, R16 are, independently of one another, H, (C_1-C_6)alkyl, or R15 and R16, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R17, R19 are, independently of one another, H or (C_1-C_6)alkyl;

R18, R20, R21 are, independently of one another, (C_1-C_6)alkyl, or aryl;

B is N(R24) or O;

R24 is H or (C_1-C_6)alkyl;

R5 is H or (C_1-C_6)alkyl;

W is N, or C(R25);

R25 is H, (C_1-C_6)alkyl, aryl, or a bond to Y;

T is N, or C(R26);

R26 is H, (C_1-C_6)alkyl, aryl, (C_0-C_8)alkylenearyl, or a bond to Y;

U is O, S, N(R27), -C(R30)=N-, or -N=C(R31);

R27, R30, R31 are, independently of one another, H, (C_1-C_6)alkyl, or a bond to Y;

Y is (C_1-C_8)alkylene, in which one or more carbons may be replaced by O, S, SO, SO_2, C(R32)(R33), CO, C(R34)(OR35), or N(R36);

R32, R33, R34, R35, R36 are, independently of one another, H, (C_1-C_6)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 3- to 8-membered ring in which one or more carbons may be replaced by O, N, or S, and the 3- to 8-membered ring may carry further substituents such as (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C_1-C_6)alkyl, or NHCO(C_1-C_6)alkyl;

R37, R38, R39, R40 are, independently of one another, H or (C_1-C_6)alkyl; and the physiologically acceptable salts thereof;

one or more anorectic active substances; and a physiologically acceptable carrier.

Claims 6-7. (canceled)

Claim 8. (currently amended): **[[The]]** **A** method **for the prophylaxis or treatment of obesity** ~~**of claim 6**~~, ~~**further**~~ comprising administering **to a mammal in need thereof** an effective amount of **[[an]]** **the** anorective active substance **of claim 5**.

Claim 9. (currently amended): **[[The]]** **A** method **for the prophylaxis or treatment of type II diabetes** ~~**of claim 7**~~, ~~**further**~~ comprising administering **to a mammal in need thereof** an effective amount of **[[an]]** **the** anorective active substance **of claim 5**.

Claims 10-15. (canceled)